Researchers evaluated the effectiveness of diabetic diets containing D-allulose among type 2 diabetes patients.
FDA rejects Alnylam’s heart disease treatment over insufficient data
The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the